Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05636618 · ClinicalTrials.gov registry record · Phase 1
Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Neuroendocrine Tumors
A Phase 1 study of Pheochromocytoma and Paraganglioma, sponsored by Perspective Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 260
- Enrollment target
- 17
- Study locations
NCT05636618: Recruiting Phase 1 study of Pheochromocytoma and Paraganglioma, sponsored by Perspective Therapeutics.
NCT05636618 is a Phase 1 study of Pheochromocytoma and Paraganglioma that is actively recruiting participants, run by Perspective Therapeutics. The registered enrollment target is 260 participants, below the 501-participant average among 14 other Pheochromocytoma trials with a reported enrollment target (48% lower). The trial reports 17 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05636618, a Phase 1 study of Pheochromocytoma and Paraganglioma, is actively recruiting participants, sponsored by Perspective Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 260 participants
- Enrollment target
- 17
- Study locations
Study Summary
This study is Phase I/IIa First-in-Human Study of \[212Pb\]VMT-α-NET Targeted Alpha-Particle Therapy for Advanced SSTR2 Positive Neuroendocrine Tumors
Primary Outcome
DLTs describe side effects of a drug that are serious enough to prevent an increase in dose
Conditions Studied
Interventions
- DRUG [203Pb]VMT-α-NET
- DRUG [212Pb]VMT-α-NET
Study Locations (17)
Michigan
- Barbara Ann Karmanos Cancer Institute - Detroit
- BAMF Health - Grand Rapids
- Michigan Health Professionals - Troy
Florida
- Mayo Clinic - Jacksonville
- Biogenix Molecular - Miami
Illinois
- The University of Chicago - Chicago
Iowa
- University of Iowa - Iowa City
Kentucky
- University of Kentucky - Lexington
Maryland
- Johns Hopkins - Baltimore
Minnesota
- Mayo Clinic - Rochester
Missouri
- Washington University - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 260 participants |
| Start Date | 2023-09-27 |
| Est. Completion | 2029-12-26 |
| Phase | Phase 1 |
What NCT05636618 shows while recruiting
NCT05636618 is an interventional study that assigns participants to a tested intervention. The registered 260 participants enrollment target is mid-sized for trials with a published cap, below the 501-participant average among 14 other Pheochromocytoma trials with a reported enrollment target (48% lower).
The record links to 6 conditions, with Pheochromocytoma appearing as the primary indexed condition, and to 2 interventions - of which [203Pb]VMT-α-NET is the first listed.
NCT05636618 lists 17 locations in 14 states (Michigan, Florida, Illinois).
Frequently Asked Questions
What is clinical trial NCT05636618 about?
NCT05636618 is a clinical study titled "Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Neuroendocrine Tumors". This study is Phase I/IIa First-in-Human Study of \[212Pb\]VMT-α-NET Targeted Alpha-Particle Therapy for Advanced SSTR2 Positive Neuroendocrine Tumors
What is the current status of trial NCT05636618?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 260 participants. The study started on 2023-09-27. Estimated completion is 2029-12-26.
What conditions does trial NCT05636618 study?
This clinical trial studies the following conditions: Pheochromocytoma, Paraganglioma, Gastroenteropancreatic Neuroendocrine Tumor, Neuroendocrine Tumors Unresectable, Neuroendocrine Tumor Metastatic.
What interventions are being tested in trial NCT05636618?
The interventions under investigation include: [203Pb]VMT-α-NET (DRUG), [212Pb]VMT-α-NET (DRUG).
Who is sponsoring clinical trial NCT05636618?
This trial is sponsored by Perspective Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05636618 being conducted?
This trial has 17 study locations across Florida, Illinois, Iowa, Kentucky, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pheochromocytoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05636618's enrollment target sits among peer trials
260 5th of 14 higher than 10 of 14 other Pheochromocytoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pheochromocytoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Diagnosis of Pheochromocytoma
RECRUITING · Phase 1
-
Somatostatin-Receptors (SSTR)-Agonist [212Pb]VMT-alpha-NET in Metastatic or Inoperable SSTR+ Gastrointestinal Neuroendocrine Tumor and Pheochromocytoma/Paraganglioma Previously Treated With Systemic Targeted Radioligand Therapy
RECRUITING · Phase 1
-
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
RECRUITING · Phase 2
-
Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma
RECRUITING · Phase 2
-
Genetic Analysis of Pheochromocytomas, Paragangliomas and Associated Conditions
RECRUITING
-
Using the EHR to Advance Genomic Medicine Across a Diverse Health System
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02283996 · 260 participants · Phase 4
Adhesive Capsulitis: Prospective Analysis of Efficacy and Financial Impact for Use of Physical Therapy in Treatment
- NCT03276793 · 260 participants · NA
Brain Connectivity in Depression
- NCT03407469 · 260 participants
Measurement of Adherence and Health-Related Quality of Life, and Health-Care Resource Utilization
- NCT03713125 · 260 participants · NA
Executive Function in Early Childhood
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI